180 Life Sciences Confirms ATNF Common Stock Listing Details
Ticker: FRMM · Form: 8-K · Filed: Jan 16, 2024 · CIK: 1690080
Complexity: simple
Sentiment: neutral
Topics: regulatory-filing, corporate-governance, administrative
TL;DR
**180 Life Sciences filed a routine 8-K confirming ATNF common stock listing details.**
AI Summary
180 Life Sciences Corp. filed an 8-K on January 16, 2024, reporting an event on January 11, 2024. This filing primarily updates the company's registration information, confirming its Common Stock, with a par value of $0.0001 per share, is traded under the symbol ATNF. For investors, this filing is a routine update, confirming the basic trading details of the stock, and doesn't indicate any new operational or financial developments that would immediately impact the stock's value.
Why It Matters
This filing is a standard administrative update, confirming the company's registered securities and trading symbol, which is important for maintaining transparency and compliance but has no direct impact on the company's financial performance or stock price.
Risk Assessment
Risk Level: low — This filing is purely administrative and does not contain any information that would introduce new risks or change the company's operational outlook.
Analyst Insight
A smart investor would recognize this as a routine compliance filing with no immediate financial implications. It's a good reminder to check for more substantive filings (like 10-K or 10-Q) for operational or financial updates.
Key Numbers
- $0.0001 — Par Value per Share (The par value of 180 Life Sciences Corp.'s Common Stock.)
Key Players & Entities
- 180 Life Sciences Corp. (company) — the registrant filing the 8-K
- ATNF (company) — trading symbol for Common Stock
- $0.0001 (dollar_amount) — par value per share of Common Stock
- January 11, 2024 (date) — date of earliest event reported
- January 16, 2024 (date) — date the 8-K was filed
FAQ
What is the purpose of this 8-K filing by 180 Life Sciences Corp.?
This 8-K filing by 180 Life Sciences Corp. is a current report under Section 13 or 15(d) of the Securities Exchange Act of 1934, primarily to report 'Other Events' as of January 11, 2024, and confirm details about its registered securities.
What is the trading symbol for 180 Life Sciences Corp.'s Common Stock?
The trading symbol for 180 Life Sciences Corp.'s Common Stock, with a par value of $0.0001 per share, is ATNF.
What is the par value of 180 Life Sciences Corp.'s Common Stock?
The par value of 180 Life Sciences Corp.'s Common Stock is $0.0001 per share.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 11, 2024.
What is the state of incorporation for 180 Life Sciences Corp.?
180 Life Sciences Corp. is incorporated in Delaware.
Filing Stats: 1,038 words · 4 min read · ~3 pages · Grade level 11.4 · Accepted 2024-01-16 08:30:22
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ATNF The NASDAQ Stock Mar
- $2,500,000 — intain stockholders' equity of at least $2,500,000. In the Company's Quarterly Report on F
- $149,327 — ny reported a stockholders' deficit of ($149,327), which is below the minimum stockholde
- $2.5 m — g its stockholders' equity to more than $2.5 million, and opt for one of the two follo
Filing Documents
- ea191607-8k_180life.htm (8-K) — 33KB
- 0001213900-24-003538.txt ( ) — 247KB
- atnf-20240111.xsd (EX-101.SCH) — 4KB
- atnf-20240111_def.xml (EX-101.DEF) — 26KB
- atnf-20240111_lab.xml (EX-101.LAB) — 36KB
- atnf-20240111_pre.xml (EX-101.PRE) — 25KB
- ea191607-8k_180life_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. As previously disclosed in the Current Report on Form 8-K, filed by 180 Life Sciences Corp. (the " Company ") with the Securities and Exchange Commission (the " Commission " or the " SEC ") on November 16, 2023, on November 15, 2023, the Company received a letter from The Nasdaq Stock Market LLC (" Nasdaq ") notifying the Company that it was not in compliance with the minimum stockholders' equity requirement for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) (the " Rule ") requires companies listed on the Nasdaq Capital Market to maintain stockholders' equity of at least $2,500,000. In the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, the Company reported a stockholders' deficit of ($149,327), which is below the minimum stockholders' equity required for continued listing pursuant to the Rule. Additionally, the Company does not meet the alternative Nasdaq continued listing standards under Nasdaq Listing Rules. Nasdaq provided the Company until January 2, 2024 to submit to Nasdaq a plan to regain compliance. We submitted the plan to regain compliance in a timely manner, and on January 11, 2023, Nasdaq advised the Company that it has determined to grant the Company an extension to regain compliance with the Rule. The terms of the extension are as follows: on or before May 13, 2024, the Company must complete certain transactions described in greater detail in the compliance plan, contemplated to result in the Company increasing its stockholders' equity to more than $2.5 million, and opt for one of the two following alternatives to evidence compliance with the Rule: Alternative 1 : The Company must furnish to the SEC and Nasdaq a publicly available report (e.g., a Form 8-K) including: 1. A disclosure of Staff's deficiency letter and the specific deficiency(ies) cited; 2. A description of the completed transaction or event that enabled the Company to satisfy the stockholders' e
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 16, 2024 180 LIFE SCIENCES CORP. By: /s/ James N. Woody, M.D., Ph.D. Name: James N. Woody, M.D., Ph.D. Title: Chief Executive Officer 2